Anti-vascular endothelial growth factors for choroidal neovascularization secondary to choroidal osteoma: Long-term results

• Main Authors: T Lekha, N Sarwate Renuka, Hari Narayan Prasad
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2015-01-01
• Series: Oman Journal of Ophthalmology
• Subjects: Choroidal neovascularization; choroidal osteoma; intravitreal bevacizumab; intravitreal ranibizumab
• Online Access: http://www.ojoonline.org/article.asp?issn=0974-620X;year=2015;volume=8;issue=3;spage=185;epage=187;aulast=Lekha

Choroidal osteoma is an uncommon benign osseous intraocular tumor typically seen unilaterally in young women. Visual loss can occur due to choroidal neovascularization (CNV) complicating osteoma. We report a rare case of bilateral choroidal osteoma with secondary CNV in a young male and the long-term results following anti-vascular endothelial growth factor (VEGF) therapy. A 30-year-old male with history of defective vision in both eyes since several years and recent worsening in the right eye (RE) since 2 months was found to have bilateral macular osteoma with CNV in the RE based on clinical evaluation, fluorescein angiography, optical coherence tomography, and ultrasonography. Intravitreal injection of ranibizumab at monthly intervals for three doses resulted in resolution of CNV and remained stable for 5 years. Recurrent CNV detected 6 years later responded to an injection of intravitreal bevacizumab and has remained stable till date. Anti-VEGF therapy stabilized the secondary CNV in our patient for 7 years with satisfactory structural and functional outcome, demonstrating the long-term efficacy of this modality of treatment.